QUREuniQure N.V.
$22.57+63% 1Y
$22.57
$9.0352 weeks$70.59
QURE in its own filings
Nothing in QURE's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
279
Events found in the filings · across 948 filings · the record starts in 2013
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 9, 2013
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountanthistorical
- 2019-04-29
- SEC comment-letter activity14 occurrences
- 2019-11-26
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as.Regulation FD disclosure · press release
- Jun 24, 2026On June 23, 2026, uniQure N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,945,055 of the Company’s …Material agreement entered · Form 8-K
- Jun 22, 2026On June 19, 2026, the Company announced preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy.Regulation FD disclosure · Form 8-K
- Jun 17, 2026On June 17, 2026, uniQure N.V. (the “Company”) issued a press release announcing its plan to submit its Biologic License Application (“BLA”) for AMT-130 in Huntington’s Disease during the third quarter of 2026.Other event · Form 8-K
- Jun 15, 2026On June 10, 2026, at the Annual Meeting, the shareholders of the Company approved proposed amendments to the Company’s articles of association (the “Articles of Association”) to (i) reflect the Dutch large company regime, (ii) increase the Company's authorized share capital, and (iii) provide that the federal district …Director or officer change · Form 8-K
- Jan 13, 2026This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…